Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chemoradiotherapy Combined With Serplulimab for Locally Advanced Cervical Cancer: A Prospective, Multicenter, Randomized, Phase II Clinical Trial

NCT07340489 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT07340489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07340489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chemoradiotherapy Combined With Serplulimab for Locally Advanced Cervical Cancer: A Prospective, Multicenter, Randomized, Phase II Clinical Trial
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
December 3, 2025
Completion date
November 30, 2027
Enrollment
216 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer